TY  - JOUR
AU  - Angel Calleja, Miguel
AU  - Albanell, Joan
AU  - Aranda, Enrique
AU  - Garcia-Foncillas, Jesus
AU  - Feliu, Anna
AU  - Rivera, Fernando
AU  - Oyaguez, Itziar
AU  - Salinas-Ortega, Laura
AU  - Soto Alvarez, Javier
PY  - 2021
DO  - 10.1136/ejhpharm-2021-002955
SN  - 2047-9956
UR  - https://hdl.handle.net/10668/25589
T2  - European journal of hospital pharmacy
AB  - Objective To assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain. Methods A 3-year budget impact analysis model was...
LA  - en
PB  - Bmj publishing group
KW  - economics
KW  - pharmaceutical
KW  - public health
KW  - medical oncology
KW  - antineoplastic agents
KW  - health care economics and organizations
KW  - Lung-cancer
KW  - Recurrent
TI  - Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
TY  - research article
VL  - 30
ER  -